Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Blood (2018) 132 (10): 1050–1063.

https://doi.org/10.1182/blood-2018-03-836601

Published: 2018

Includes: Supplemental data

Journal Articles

Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo

Cirino Botta, MD, Marco Rossi, MD, Maria Rita Pitari, PhD, Annamaria Gullà, MD, Teresa Del Giudice, MD, Eugenio Morelli, MD, Eleonora Iuliano, MD, Emanuela Altomare, PhD, Nicola Amodio, PhD, Maria Teresa Di Martino, PhD, Pierpaolo Correale, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 4489.

https://doi.org/10.1182/blood.V122.21.4489.4489

Published: 2013

Journal Articles

Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease

Maria Rita Pitari, PhD, Marco Rossi, MD, Cirino Botta, MD, Eugenio Morelli, MD, Annamaria Gullà, MD, Eleonora Iuliano, MD, Teresa Del Giudice, MD, Nicola Amodio, PhD, Maria Teresa Di Martino, PhD, Fortunato Morabito, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 683.

https://doi.org/10.1182/blood.V122.21.683.683

Published: 2013

Journal Articles

Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease

Marco Rossi, MD, Maria Rita Pitari, PhD student, Nicola Amodio, PhD, Maria Teresa Di Martino, PhD, Emanuela Leone, PhD, Francesco Conforti, MD, Francesco Maria Paolino, PhD student, Cirino Botta, MD, Teresa Del Giudice, MD, Eleonora Iuliano, MD, Manlio Ferrarini, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2012) 120 (21): 3960.

https://doi.org/10.1182/blood.V120.21.3960.3960

Published: 2012

Journal Articles

MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence

Maria Teresa Di Martino, PhD, Emanuela Leone, PhD, Nicola Amodio, PhD, Umberto Foresta, PhD, Marta Lionetti, PhD, Maria Rita Pitari, PhD, Maria Eugenia Gallo Cantafio, PhD, Annamaria Gullà, Eugenio Morelli, MD, Marzia Leotta, Vera Tomaino, PhD, Marco Rossi, MD, Massimo Negrini, PhD, Manlio Ferrarini, MD, Antonino Neri, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2011) 118 (21): 2910.

https://doi.org/10.1182/blood.V118.21.2910.2910

Published: 2011

NARROW

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo

Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease

Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease

MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence

Email alerts

ASH Publications

American Society of Hematology

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo

Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease

Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease

MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only